最近浏览

实时行情

意见反馈

Intra-Cellular Therapies, Inc.

NASDAQ:ITCI 延时15分钟 已退市
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 贝塔系数：
    每股收益：
成交量

董事会

Sharon L. Mates
Sharon L. Mates is the founder of ITI, Inc. ( New York), founded in 2002, serving as Chairman, President & Chief Executive Officer. Dr. Mates was the founder of Intra-Cellular Therapies, Inc., founded in 2002, serving as Chairman, President & Chief Executive Officer in 2013 and as Chief Executive Officer starting in 2025. Dr. Mates was the founder of Functional Genetics, Inc., founded in 2000, serving as Chairman & Chief Executive Officer from 2000 to 2003. Current jobs include Director-Emerging Company Section at Biotechnology Innovation Organization, Independent Director at MedinCell SA starting in 2025, Independent Director at Benitec Biopharma, Inc. starting in 2025, and Advisor at The New York City Investment Fund Manager, Inc. Former jobs include Chairman at New York Biotechnology Association, Inc., President & Director at North American Vaccine, Inc. from 1989 to 1998, Director-Biotechnology Institute at the University of Maryland, and Director at Gilda's Club New York City, Inc. Education includes a doctorate from the University of Washington conferred in 1981 and undergraduate studies at The Ohio State University.
Joel S. Marcus
Mr. Joel S. Marcus, CPA, is an Independent Director at Applied Therapeutics, Inc., an Independent Director at Intra-Cellular Therapies, Inc., an Executive Chairman & Founder at Alexandria Venture Investments LLC, an Executive Chairman at Alexandria Real Estate Equities, Inc., an Advisor at The New York City Investment Fund Manager, Inc., a Chairman & Chief Executive Officer at Alexandria Agtech/Climate Innovation Acquisition Corp. and a Managing Member at Alexandria Equities LLC. He is on the Board of Directors at AltPep Corp., Navy SEAL Foundation, Applied Therapeutics, Inc., Biotechnology Innovation Organization, MeiraGTx Ltd., Biohealth Innovation, Inc., Intra-Cellular Therapies, Inc., Foundation for the National Institutes of Health, Inc., ITI, Inc. (New York), Accelerator Services Corp, Emily Krzyzewski Family Life Center, Inc., Massachusetts Biotechnology Council, Medblue Incubator, Inc., National September 11 Memorial & Museum at the World Trade, New York Biotechnology Association, Inc., NewYorkBIO, NYU Schack Institute of Real Estate, Proniras Corp., Reactive Biosciences, Inc., Robin Hood Foundation, The 9/11 Memorial & Museum, The National Medal of Honor Museum Foundation, The Parker Institute For Cancer Immunotherapy, The Partnership for New York City, Inc., The Scripps Research Institute, TOPGUN Association and National Association of Real Estate Investment Trusts, Inc. Mr. Marcus was previously employed as an Independent Director by Frequency Therapeutics, Inc., a Co-Founder by Alexandria Summit, an Independent Director by MeiraGTx Holdings Plc, an Independent Director by Atara Biotherapeutics, Inc, Partner by Brobeck, Phleger & Harrison LLP He received his undergraduate degree from the University of California, Los Angeles and a graduate degree from the University of California, Los Angeles.
Rory Balfour Riggs
Mr. Rory B. Riggs is a Chief Executive Officer & Trustee at WEBs ETF Trust, a Chief Executive Officer at Syntax Analytics LLC, a CEO (Founder) at Locus Analytics LLC, an Executive Chairman (Founder) at Syntax LLC, a General Partner at Scientia Ventures LLC, a Chairman, CEO (Co-founder) at Cibus Corp., an Independent Director at StageZero Life Sciences Ltd., a Chairman at Cibus Ltd., a Chairman at Nucelis, Inc., a Founder & Chief Executive Officer at Syntax Advisors LLC and a Managing Member at Balfour Venture Partners. He is on the Board of Directors at WEBs ETF Trust, ITI, Inc. (New York), Cibus, Inc., StageZero Life Sciences Ltd. and Nuredis, Inc. Mr. Riggs was previously employed as an Independent Director by Intra-Cellular Therapies, Inc., a Managing Member by New Ventures I LLC, an Independent Director by Royalty Pharma Plc, a Board Member (Co-founder) by FibroGen, Inc., a President & Chief Executive Officer by The RF&P Corp., a President, Chief Financial Officer & Director by Biomatrix, Inc., a Managing Director by PaineWebber, Inc., a Managing Member by Balfour LLC, a Principal by Pacific Media Partners, Inc. /Old/, an Associate by Strategic Planning Associates, and a Co-founder and Chairman/Director by Sugen, Inc. He also served on the board at eReceivables Inc., ChondroGene Ltd., Medrium, Inc., Patient Choice Healthcare, Inc. and Sparton Corp. He received his undergraduate degree from Middlebury College and an MBA from The Trustees of Columbia University in The City of New York.
Robert L. van Nostrand
Robert L. van Nostrand is currently the Independent Chairman at Yield10 Bioscience, Inc. He is also the Treasurer & Director at New York Biotechnology Association, Inc. Additionally, he serves as the Director at Brany LLC, Lead Independent Director at Intra-Cellular Therapies, Inc., Director at ITI, Inc. (New York), Director at Sellas Life Sciences Group Ltd., Independent Director at SELLAS Life Sciences Group, Inc., Director at LikeMinds, Inc. (Massachusetts), and Member at Association of Biofinance Officers. In his former positions, Mr. van Nostrand served as the Chairman at Farmingdale College Foundation. He was also an Independent Director at Achillion Pharmaceuticals, Inc. from 2007 to 2020. He held the position of Director at Achillion Pharmaceuticals, Inc., Director at Apex Bioventures Acquisition Corp., Independent Director at Enumeral Biomedical Holdings, Inc., Director at Apex Bioventures LLC, Director at Enumeral Biomedical Corp., Director at SELLAS Life Sciences Group, Inc., Chief Compliance Officer & Senior Vice President at OSI Pharmaceuticals, Inc. from 2005 to 2007, Chief Financial Officer & Executive Vice President at Applied Genetics, Inc. Dermatics from 2007 to 2008, Chief Financial Officer & Executive Vice President at Aureon Biosciences, Inc. in 2010, and Manager at Touche Ross & Co. He also served as the Chief Financial Officer & Executive Vice President at Aureon Laboratories, Inc.Mr. van Nostrand obtained his undergraduate degree from Long Island University.
Eduardo Rene Salas
Eduardo Rene Salas currently works at ADMA Biologics, Inc., as Independent Director from 2024. Ms. Salas also formerly worked at Embody, Inc., as Director from 2021 to 2023, Intra-Cellular Therapies, Inc., as Independent Director from 2022 to 2025, Ernst & Young LLP, as Audit Partner from 2002 to 2019, and Wellstat Management Co. LLC, as Chief Financial Officer from 2020 to 2022. Ms. Salas received her undergraduate degree from the University of Texas at San Antonio.